SEC Form 4 · accession 0001493152-26-031846
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vuong Trieu
Officer — CHAIRMAN AND CEO · Director · 10% Owner
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 3:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000908259
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | P | 240,000 | $0.0431 | A | 94,124,319 | D | |
| Common Stock | holding | — | — | — | 16,780,384 | I | By Autotelic Inc. | |
| Common Stock | holding | — | — | — | 6,872,529 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431.